GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (MEX:NVS N) » Definitions » Change In Receivables

Novartis AG (MEX:NVS N) Change In Receivables : MXN-14,645 Mil (TTM As of Jun. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Novartis AG Change In Receivables?

Novartis AG's change in receivables for the quarter that ended in Jun. 2025 was MXN-3,144 Mil. It means Novartis AG's Accounts Receivable increased by MXN3,144 Mil from Mar. 2025 to Jun. 2025 .

Novartis AG's change in receivables for the fiscal year that ended in Dec. 2024 was MXN-19,417 Mil. It means Novartis AG's Accounts Receivable increased by MXN19,417 Mil from Dec. 2023 to Dec. 2024 .

Novartis AG's Accounts Receivable for the quarter that ended in Jun. 2025 was MXN170,517 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Novartis AG's Days Sales Outstanding for the three months ended in Jun. 2025 was 55.70.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Novartis AG's liquidation value for the three months ended in Jun. 2025 was MXN-854,761 Mil.


Novartis AG Change In Receivables Historical Data

The historical data trend for Novartis AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Change In Receivables Chart

Novartis AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,725.20 -7,220.93 -7,739.91 -25,529.27 -19,416.66

Novartis AG Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9,178.37 6,458.42 3,378.62 -21,337.90 -3,144.48

Novartis AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-14,645 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novartis AG  (MEX:NVS N) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Novartis AG's Days Sales Outstanding for the quarter that ended in Jun. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=170517.235/279350.011*91
=55.70

2. In Ben Graham's calculation of liquidation value, Novartis AG's accounts receivable are only considered to be worth 75% of book value:

Novartis AG's liquidation value for the quarter that ended in Jun. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=131804.4-1173831.157+0.75 * 170517.235+0.5 * 118755.764
=-854,761

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novartis AG Change In Receivables Related Terms

Thank you for viewing the detailed overview of Novartis AG's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG Business Description

Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Novartis AG Headlines

No Headlines